Patents by Inventor Masaru Takayanagi
Masaru Takayanagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9440980Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: April 25, 2014Date of Patent: September 13, 2016Assignee: EA PHARMA CO., LTD.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20140309135Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: April 25, 2014Publication date: October 16, 2014Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki FUKUCHI, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8772281Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: December 10, 2012Date of Patent: July 8, 2014Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8357680Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: October 7, 2009Date of Patent: January 22, 2013Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8299064Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: GrantFiled: March 4, 2011Date of Patent: October 30, 2012Assignee: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Patent number: 8227506Abstract: Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.Type: GrantFiled: August 2, 2007Date of Patent: July 24, 2012Assignee: Ajinomoto., Inc.Inventors: Masaru Takayanagi, Shunji Takehana, Kayo Otani, Yuki Saitou
-
Publication number: 20110172416Abstract: Provision of a novel amidine derivative or a pharmaceutically acceptable salt thereof having an activated blood coagulation factor X-inhibitory activity. A compound represented by the formula (I) wherein each symbol is as defined above, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 11, 2011Publication date: July 14, 2011Applicant: Ajinomoto Co., Inc.Inventors: Kayo MATSUMOTO, Masayuki Sugiki, Masaru Takayanagi, Yasuko Nogi, Shinya Taniguchi, Satoko Ueno, Yoshiaki Shirai
-
Publication number: 20110160191Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: Ajinomoto Co., Inc.Inventors: Ryusuke HIRAMA, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Patent number: 7951799Abstract: The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.Type: GrantFiled: October 29, 2007Date of Patent: May 31, 2011Assignee: Ajinomoto Co., Inc.Inventors: Hideyuki Tanaka, Wataru Miyanaga, Masaru Takayanagi, Ryusuke Hirama, Yoko Kageyama, Tatsuya Ishikawa, Itsuya Tanabe, Yoriko Okamatsu
-
Patent number: 7928101Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: GrantFiled: May 1, 2006Date of Patent: April 19, 2011Assignee: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Publication number: 20100105731Abstract: Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.Type: ApplicationFiled: August 2, 2007Publication date: April 29, 2010Applicant: Ajinomoto Co., Inc.Inventors: Masaru TAKAYANAGI, Shunji TAKEHANA, Kayo OTANI, Yuki SAITOU
-
Publication number: 20100093055Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: October 7, 2009Publication date: April 15, 2010Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 7396844Abstract: Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided.Type: GrantFiled: July 19, 1999Date of Patent: July 8, 2008Assignee: Ajinomoto Co., Inc.Inventors: Masaru Takayanagi, Kazuyuki Sagi, Tadakiyo Nakagawa, Masahiro Yamanashi, Takashi Kayahara, Shunji Takehana, Yumiko Fukuda, Mitsuo Takahashi, Masataka Shoji
-
Publication number: 20080108604Abstract: The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.Type: ApplicationFiled: October 29, 2007Publication date: May 8, 2008Applicant: Ajinomoto Co., Inc.Inventors: Hideyuki Tanaka, Wataru Miyanaga, Masaru Takayanagi, Ryusuke Hirama, Yoko Kageyama, Tatsuya Ishikawa, Itsuya Tanabe, Yoriko Okamatsu
-
Publication number: 20080021065Abstract: Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.Type: ApplicationFiled: August 2, 2007Publication date: January 24, 2008Applicant: AJINOMOTO CO. INCInventors: Masaru Takayanagi, Shunji Takehana, Kayo Otani, Yuki Saitou
-
Publication number: 20060194789Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: ApplicationFiled: May 1, 2006Publication date: August 31, 2006Applicant: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Patent number: 6825181Abstract: Aminoisoquinoline derivatives of the following formulae or analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an excellent effect of inhibiting activated blood-coagulation factor X, and they are useful as anticoagulants or agents for preventing or treating thrombi or emboli.Type: GrantFiled: September 19, 2000Date of Patent: November 30, 2004Assignee: Ajinomoto Co., Inc.Inventors: Tadakiyo Nakagawa, Shingo Makino, Kazuyuki Sagi, Masaru Takayanagi, Takashi Kayahara, Shunji Takehana